Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

Combining TACE and SBRT offers a promising treatment for large HCC tumors, addressing TACE's limitations in intermediate-stage cases. Technological advancements have improved SBRT's precision and ...

Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, ...

Transcatheter arterial chemoembolization alone and with microwave ablation yielded comparable overall survival rates in patients with recurrent small hepatocellular carcinoma after resection, per ...

Please provide your email address to receive an email when new articles are posted on . Postprocedural imaging showed 10% of patients had new portal vein thrombosis after transarterial ...

In this review we will discuss TACE, TAE and TOCE in detail. The TACE procedure consists of the injection of anticancer drugs mixed with or without lipiodol into the hepatic artery followed by the ...

There's a possible new standard of care on the horizon for unresectable hepatocellular carcinoma (HCC) after years of failed attempts to improve upon the outcomes of the current protocol — stand-alone ...

The addition of PD-1 inhibitors to first-line treatment with transarterial chemoembolization (TACE) plus lenvatinib for hepatocellular carcinoma (HCC). “PD-1 inhibitors have been recognized as an ...

SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.

Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer.

The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers ...